TSPYl5 SNPs

Association with plasma estradiol concentrations and aromatase expression

Mohan Liu, James N. Ingle, Brooke L. Fridley, Aman U. Buzdar, Mark E. Robson, Michiaki Kubo, Liewei Wang, Anthony Batzler, Gregory D. Jenkins, Tracy L. Pietrzak, Erin E. Carlson, Matthew P. Goetz, Donald W. Northfelt, Edith A. Perez, Clark V. Williard, Daniel J. Schaid, Yusuke Nakamura, Richard M. Weinshilboum

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We performed a discovery genome-wide association study to identify genetic factors associated with variation in plasma estradiol (E2) concentrations using DNA from 772 postmenopausal women with estrogen receptor (ER)-positive breast cancer prior to the initiation of aromatase inhibitor therapy. Association analyses showed that the single nucleotide polymorphisms (SNP) (rs1864729) with the lowest P value (P = 3.49E-08), mapped to chromosome 8 near TSPYL5. We also identified 17 imputed SNPs in or near TSPYL5 with P values <; 5E-08, one of which, rs2583506, created a functional estrogen response element. We then used a panel of lymphoblastoid cell lines (LCLs) stably transfected with ERβ with known genome-wide SNP genotypes to demonstrate that TSPYL5 expression increased after E2 exposure of cells heterozygous for variant TSPYL5 SNP genotypes, but not in those homozygous for wild-type alleles. TSPYL5 knockdown decreased, and overexpression increased aromatase (CYP19A1) expression in MCF-7 cells, LCLs, and adipocytes through the skin/adipose (I.4) promoter. Chromatin immunoprecipitation assay showed that TSPYL5 bound to the CYP19A1 I.4 promoter. A putative TSPYL5 binding motif was identified in 43 genes, and TSPYL5 appeared to function as a transcription factor for most of those genes. In summary, genome-wide significant SNPs in TSPYL5 were associated with elevated plasma E2 in postmenopausal breast cancer patients. SNP rs2583506 created a functional estrogen response element, and LCLs with variant SNP genotypes displayed increased E2-dependent TSPYL5 expression. TSPYL5 induced CYP19A1 expression and that of many other genes. These studies have revealed a novel mechanism for regulating aromatase expression and plasma E2 concentrations in postmenopausal women with ER(+) breast cancer.

Original languageEnglish
Pages (from-to)657-670
Number of pages14
JournalMolecular Endocrinology
Volume27
Issue number4
DOIs
Publication statusPublished - 01-04-2013

Fingerprint

Aromatase
Single Nucleotide Polymorphism
Estradiol
Estrogen Receptors
Genotype
Response Elements
Breast Neoplasms
Cell Line
Estrogens
Genome
Genes
Chromosomes, Human, Pair 8
Aromatase Inhibitors
Chromatin Immunoprecipitation
Genome-Wide Association Study
MCF-7 Cells
Adipocytes
Transcription Factors
Alleles
Skin

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Endocrinology

Cite this

Liu, M., Ingle, J. N., Fridley, B. L., Buzdar, A. U., Robson, M. E., Kubo, M., ... Weinshilboum, R. M. (2013). TSPYl5 SNPs: Association with plasma estradiol concentrations and aromatase expression. Molecular Endocrinology, 27(4), 657-670. https://doi.org/10.1210/me.2012-1397
Liu, Mohan ; Ingle, James N. ; Fridley, Brooke L. ; Buzdar, Aman U. ; Robson, Mark E. ; Kubo, Michiaki ; Wang, Liewei ; Batzler, Anthony ; Jenkins, Gregory D. ; Pietrzak, Tracy L. ; Carlson, Erin E. ; Goetz, Matthew P. ; Northfelt, Donald W. ; Perez, Edith A. ; Williard, Clark V. ; Schaid, Daniel J. ; Nakamura, Yusuke ; Weinshilboum, Richard M. / TSPYl5 SNPs : Association with plasma estradiol concentrations and aromatase expression. In: Molecular Endocrinology. 2013 ; Vol. 27, No. 4. pp. 657-670.
@article{a5272b3d7d674603b762993f0ebadad5,
title = "TSPYl5 SNPs: Association with plasma estradiol concentrations and aromatase expression",
abstract = "We performed a discovery genome-wide association study to identify genetic factors associated with variation in plasma estradiol (E2) concentrations using DNA from 772 postmenopausal women with estrogen receptor (ER)-positive breast cancer prior to the initiation of aromatase inhibitor therapy. Association analyses showed that the single nucleotide polymorphisms (SNP) (rs1864729) with the lowest P value (P = 3.49E-08), mapped to chromosome 8 near TSPYL5. We also identified 17 imputed SNPs in or near TSPYL5 with P values <; 5E-08, one of which, rs2583506, created a functional estrogen response element. We then used a panel of lymphoblastoid cell lines (LCLs) stably transfected with ERβ with known genome-wide SNP genotypes to demonstrate that TSPYL5 expression increased after E2 exposure of cells heterozygous for variant TSPYL5 SNP genotypes, but not in those homozygous for wild-type alleles. TSPYL5 knockdown decreased, and overexpression increased aromatase (CYP19A1) expression in MCF-7 cells, LCLs, and adipocytes through the skin/adipose (I.4) promoter. Chromatin immunoprecipitation assay showed that TSPYL5 bound to the CYP19A1 I.4 promoter. A putative TSPYL5 binding motif was identified in 43 genes, and TSPYL5 appeared to function as a transcription factor for most of those genes. In summary, genome-wide significant SNPs in TSPYL5 were associated with elevated plasma E2 in postmenopausal breast cancer patients. SNP rs2583506 created a functional estrogen response element, and LCLs with variant SNP genotypes displayed increased E2-dependent TSPYL5 expression. TSPYL5 induced CYP19A1 expression and that of many other genes. These studies have revealed a novel mechanism for regulating aromatase expression and plasma E2 concentrations in postmenopausal women with ER(+) breast cancer.",
author = "Mohan Liu and Ingle, {James N.} and Fridley, {Brooke L.} and Buzdar, {Aman U.} and Robson, {Mark E.} and Michiaki Kubo and Liewei Wang and Anthony Batzler and Jenkins, {Gregory D.} and Pietrzak, {Tracy L.} and Carlson, {Erin E.} and Goetz, {Matthew P.} and Northfelt, {Donald W.} and Perez, {Edith A.} and Williard, {Clark V.} and Schaid, {Daniel J.} and Yusuke Nakamura and Weinshilboum, {Richard M.}",
year = "2013",
month = "4",
day = "1",
doi = "10.1210/me.2012-1397",
language = "English",
volume = "27",
pages = "657--670",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "4",

}

Liu, M, Ingle, JN, Fridley, BL, Buzdar, AU, Robson, ME, Kubo, M, Wang, L, Batzler, A, Jenkins, GD, Pietrzak, TL, Carlson, EE, Goetz, MP, Northfelt, DW, Perez, EA, Williard, CV, Schaid, DJ, Nakamura, Y & Weinshilboum, RM 2013, 'TSPYl5 SNPs: Association with plasma estradiol concentrations and aromatase expression', Molecular Endocrinology, vol. 27, no. 4, pp. 657-670. https://doi.org/10.1210/me.2012-1397

TSPYl5 SNPs : Association with plasma estradiol concentrations and aromatase expression. / Liu, Mohan; Ingle, James N.; Fridley, Brooke L.; Buzdar, Aman U.; Robson, Mark E.; Kubo, Michiaki; Wang, Liewei; Batzler, Anthony; Jenkins, Gregory D.; Pietrzak, Tracy L.; Carlson, Erin E.; Goetz, Matthew P.; Northfelt, Donald W.; Perez, Edith A.; Williard, Clark V.; Schaid, Daniel J.; Nakamura, Yusuke; Weinshilboum, Richard M.

In: Molecular Endocrinology, Vol. 27, No. 4, 01.04.2013, p. 657-670.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TSPYl5 SNPs

T2 - Association with plasma estradiol concentrations and aromatase expression

AU - Liu, Mohan

AU - Ingle, James N.

AU - Fridley, Brooke L.

AU - Buzdar, Aman U.

AU - Robson, Mark E.

AU - Kubo, Michiaki

AU - Wang, Liewei

AU - Batzler, Anthony

AU - Jenkins, Gregory D.

AU - Pietrzak, Tracy L.

AU - Carlson, Erin E.

AU - Goetz, Matthew P.

AU - Northfelt, Donald W.

AU - Perez, Edith A.

AU - Williard, Clark V.

AU - Schaid, Daniel J.

AU - Nakamura, Yusuke

AU - Weinshilboum, Richard M.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - We performed a discovery genome-wide association study to identify genetic factors associated with variation in plasma estradiol (E2) concentrations using DNA from 772 postmenopausal women with estrogen receptor (ER)-positive breast cancer prior to the initiation of aromatase inhibitor therapy. Association analyses showed that the single nucleotide polymorphisms (SNP) (rs1864729) with the lowest P value (P = 3.49E-08), mapped to chromosome 8 near TSPYL5. We also identified 17 imputed SNPs in or near TSPYL5 with P values <; 5E-08, one of which, rs2583506, created a functional estrogen response element. We then used a panel of lymphoblastoid cell lines (LCLs) stably transfected with ERβ with known genome-wide SNP genotypes to demonstrate that TSPYL5 expression increased after E2 exposure of cells heterozygous for variant TSPYL5 SNP genotypes, but not in those homozygous for wild-type alleles. TSPYL5 knockdown decreased, and overexpression increased aromatase (CYP19A1) expression in MCF-7 cells, LCLs, and adipocytes through the skin/adipose (I.4) promoter. Chromatin immunoprecipitation assay showed that TSPYL5 bound to the CYP19A1 I.4 promoter. A putative TSPYL5 binding motif was identified in 43 genes, and TSPYL5 appeared to function as a transcription factor for most of those genes. In summary, genome-wide significant SNPs in TSPYL5 were associated with elevated plasma E2 in postmenopausal breast cancer patients. SNP rs2583506 created a functional estrogen response element, and LCLs with variant SNP genotypes displayed increased E2-dependent TSPYL5 expression. TSPYL5 induced CYP19A1 expression and that of many other genes. These studies have revealed a novel mechanism for regulating aromatase expression and plasma E2 concentrations in postmenopausal women with ER(+) breast cancer.

AB - We performed a discovery genome-wide association study to identify genetic factors associated with variation in plasma estradiol (E2) concentrations using DNA from 772 postmenopausal women with estrogen receptor (ER)-positive breast cancer prior to the initiation of aromatase inhibitor therapy. Association analyses showed that the single nucleotide polymorphisms (SNP) (rs1864729) with the lowest P value (P = 3.49E-08), mapped to chromosome 8 near TSPYL5. We also identified 17 imputed SNPs in or near TSPYL5 with P values <; 5E-08, one of which, rs2583506, created a functional estrogen response element. We then used a panel of lymphoblastoid cell lines (LCLs) stably transfected with ERβ with known genome-wide SNP genotypes to demonstrate that TSPYL5 expression increased after E2 exposure of cells heterozygous for variant TSPYL5 SNP genotypes, but not in those homozygous for wild-type alleles. TSPYL5 knockdown decreased, and overexpression increased aromatase (CYP19A1) expression in MCF-7 cells, LCLs, and adipocytes through the skin/adipose (I.4) promoter. Chromatin immunoprecipitation assay showed that TSPYL5 bound to the CYP19A1 I.4 promoter. A putative TSPYL5 binding motif was identified in 43 genes, and TSPYL5 appeared to function as a transcription factor for most of those genes. In summary, genome-wide significant SNPs in TSPYL5 were associated with elevated plasma E2 in postmenopausal breast cancer patients. SNP rs2583506 created a functional estrogen response element, and LCLs with variant SNP genotypes displayed increased E2-dependent TSPYL5 expression. TSPYL5 induced CYP19A1 expression and that of many other genes. These studies have revealed a novel mechanism for regulating aromatase expression and plasma E2 concentrations in postmenopausal women with ER(+) breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84875482213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875482213&partnerID=8YFLogxK

U2 - 10.1210/me.2012-1397

DO - 10.1210/me.2012-1397

M3 - Article

VL - 27

SP - 657

EP - 670

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 4

ER -